Lumbar Radiculopathy (Sciatica)| Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast - 2030
発行: Mellalta Meets LLP
ページ情報: 英文 181 Pages
The Lumbar Radiculopathy/LSR (Sciatica) therapeutic market is expected to experience high growth throughout our study period, increasing from 2017 to 2030. The main drivers of this growth will be the launch of new drugs in chronic LSR/sciatica setting, e.g., Dexamethasone sodium phosphate gel / SEMDEXA (Scilex Pharmaceuticals), Condoliase / HERNICORE (Seikagaku Corporation / Ferring Pharmaceuticals), ETX-810 (Eliem Therapeutics Inc), Extended-release Clonidine / Clonidine micropellet (Sollis Therapeutics) and extended-release dexamethasone (SpineThera).
Sciatica (also refferred to as Lumbar Radiculopathy or lumbosacral radiculopathy (LSR) , which is medically defined as lumbar radiculopathy, is nerve pain that originates deep in the buttock and travels down to the thigh and/or leg. Sciatica is commonly caused when a herniated disc or narrowing of the bony opening for spinal nerves (foraminal spinal stenosis) compresses a nerve root in the lumbar spine.
Approximately 90% of cases of sciatica is due to spinal disc herniation pressing on one of the lumbar or sacral nerve roots, followed by spinal stenosis or the narrowing of the spinal canal which is another reason for sciatica pain. Sciatica may also occur during pregnancy and up to 8% cases rarely arises from Piriformis syndrome in which the shortening of piriformis muscle exerts pressure on the sciatic nerve. However, Disc herniation, back sprain, shingles, and degenerative lumbar spine can all cause acute sciatica, lasting from days to weeks, but degeneration of the lumbar spine and discs leads to chronic sciatica that persists unless a surgical intervention is performed.
Sciatica is often characterized by extreme pain and inflammation. Sciatica can occur at any age but often effects men beginning in their 40s and women in their 50s and 60s.
The criteria used to diagnose Lumbar Radiculopathy (Sciatica) are those of the diagnostic guidelines provided by various governing bodies. According to these criteria and the KOL perspective, there is no specific tests for sciatica and current diagnosis are mainly done by using tools like neuroimaging, MRI scan, CT myelography, Electromyography (EMG), straight leg raising test and Cerebrospinal fluid analysis. As the diagnosis of lumbosacral radiculopathy (Sciatica) is not specific, there are other conditions that can be differentiated due to the radicular pain. The other conditions in the differential diagnosis of lumbosacral radiculopathy include herniated disc, lumbosacral plexopathy, lumbar spinal stenosis, mononeuropathies, diabetic amyotrophy, cauda equina syndrome, and non-radicular back pain.
"The total prevalent cases of lumbosacral radicular pain (LSR) / sciatica in the G7 countries are projected to increase from 24 million in 2017 to XX million by 2030 with a CAGR of XX% for the study period (2017-2030 ). The United States was estimated to have the highest prevalence of lumbar radiculopathy (sciatica) cases in 2017."
Current market of Sciatica holds treatment options that are supportive like a conservative (nonsurgical) and surgical approaches. Conservative treatment of sciatica further includes physical therapy, behavioral therapies, or pharmacological therapies. Pharmacological therapies includes medications such as non-steroidal anti-inflammatory drugs (NSAIDs), epidural steroid injections (ESIs), opioids etc. that has been used over-the counter and were observed to reduce the swelling and sciatic pain. Patients are treated with a wide variety of medication first and referred for epidural steroid injections as a second step if they fail to respond to pain medication.
"Epidural injections are common. An estimated 10 million to 11 million injections (2.2 million in the Medicare population) are administered annually in the United States. Despite of widespread utilization of ESIs, concerns persist in the market about particulate steroids and potential side effect and safety concerns (e.g., stroke) from current off-label use. As a result, a significant unmet medical need exists within the market for a potent, non-particulate ESI formulation that demonstrates safety and effectiveness in controlled clinical trial evaluations. Therefore, current sciatica market exhibit a critical unmet need to improve the quality of life of the patients since there are no FDA approved therapies to treat the indication and the off-label therapies have several side effects."
The Lumbar Radiculopathy / LSR (Sciatica) market is expected to see high growth during the forecast period. The market in the G7 countries is expected to reach $18 billion in 2030. The lumbar radiculopathy (sciatica) treatment market is divided into acute and chronic lumbar radiculopathy.
"Approximately 70% of acute cases will be recovered with primary treatments and the remaining 30% are expected to fall into the chronic group, referred to here as chronic LSR. "
The market for acute lumbar radiculopathy (Sciatica) is relatively large compared to the market for chronic lumbar radiculopathy (Sciatica) due to the high number of patients and the increase in primary care prescriptions each year.